Σάββατο 27 Αυγούστου 2016

Novel strategies to discover effective drug targets in metabolic and immune therapy for glioblastoma.

Novel strategies to discover effective drug targets in metabolic and immune therapy for glioblastoma.

Curr Cancer Drug Targets. 2016 May 12;

Authors: Wang G, Fu XL, Wang JJ, Guan R, Tang XJ

Abstract
Glioblastoma multiforme is a common primary brain tumor, which exhibits an imbalance between glioma cell growth and glucose metabolism. Recent discoveries have found the multiple pathways and downstream genes are involved in the dysregulated metabolic pathway allows tumor to start and progress, which is critical to the patients with glioblastoma associated with significant systemic and immunosuppression. Moreover, immune microenvironment is considered a major obstacle to generating an effective antitumor immune response. Therefore, identification of patient-specific tumor antigens through highly personalized approach, and effective combination with other therapeutic modalities such as molecular agents targeting tumor metabolic oncogene addiction and potent host immune modulators, which may provide targets for more effective therapeutic strategies for glioblastoma. In this review, we aim to highlight to the most recent findings regarding glucose uptake and proliferation, cell mobility and to expand our investigations and more comprehensive examine different aspects of glucose metabolism in glioblastoma, such as pentose phosphate pathway (PPP) and its enzymes, metabolic modulation of genetics and epigenetics and key metabolic regulators, importantly, tumor cell-induced glucose deprivation inhibits T-cell glycolysis and immunogenic functions. Furthermore, this review will concentrate on how to discover effective drug targets to regulate glucose metabolism in tumor and T cell growth for future glioblastoma therapies, and the challenges facing the field of metabolism in tumor immune microenviroment.

PMID: 27562399 [PubMed - as supplied by publisher]



from Cancer via ola Kala on Inoreader http://ift.tt/2boCTfr
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου